Pulse Biosciences, Inc. (PLSE) Advances Cardiac Care with FDA-Approved Atrial Fibrillation Trial

We recently compiled a list of the 12 Healthcare Stocks with Insider Buying in 2025. Pulse Biosciences, Inc. is one of them.

Pulse Biosciences, Inc. (NASDAQ:PLSE) is advancing bioelectric medicine through its proprietary Nano-Pulse Stimulation (NPS) technology, targeting immuno-oncology, dermatology, and cardiac ablation. The company’s Nanosecond Pulsed Field Ablation (nsPFA) system offers non-thermal cellular treatment approaches and has gained FDA Breakthrough Device Designation for its potential to transform cardiac therapies.

A key milestone came with FDA approval to initiate a clinical study of the nsPFA Cardiac Surgery System for atrial fibrillation in September 2025, enrolling up to 136 patients across 20 sites, including international locations. This positions PLSE at the forefront of innovative cardiac treatments and highlights why it is closely monitored among stocks with insider buying.

In September 2025, Pulse Biosciences, Inc. (NASDAQ:PLSE) reported its first successful procedures in the PRECISE-BTN study, evaluating its nsPFA Percutaneous Electrode System for benign thyroid nodules (BTNs). The multicenter trial involves 50 patients across four sites, focusing on safety, nodule volume reduction, symptom relief, and quality of life. Early results are promising, showing significant reductions in nodule size.

While we acknowledge the potential of PLSE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy NOW 

Disclosure: None.